✦ LIBER ✦

P.08.17 SAFETY AND TOLERABILITY OF SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH SEVERE IMPAIRMENT OF LIVER FUNCTION: A PROSPECTIVE STUDY

✍ Scribed by A.L. Inghilesi; D. Gallori; L. Antonuzzo; F. Pasquinelli; U. Arena; G. Laffi; F. Di Costanzo; F. Marra

Book ID: 118648604
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 55 KB
Volume: 44
Category: Article
ISSN: 1590-8658
DOI: 10.1016/s1590-8658(12)60388-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.1.66: SAFETY AND EFFECTIVENESS OF TREA

P.1.66: SAFETY AND EFFECTIVENESS OF TREATMENT WITH SORAFENIB IN ELDERLY CIRRHOTIC PATIENTS AFFECTED BY ADVANCED HEPATOCELLULAR CARCINOMA

✍ T. Raffaella; A. Galeota Lanza; F. Lampasi; M. De Luca; M.T. Tartaglione; R. Pac 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

The use of single-agent sorafenib in the

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis : A retrospective analysis of efficacy, safety, and survival benefits

✍ Joanne Chiu; Yuen Fong Tang; Tzy-Jyun Yao; Ashley Wong; Hilda Wong; Roland Leung 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 792 KB

The safety and efficacy of transcatheter

The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction : A prospective controlled study

✍ Hyo-Suk Lee; Joo Sung Kim; Il Ju Choi; Jin Wook Chung; Jae Hyung Park; Chung Yon 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 3 views

## Background: Transcatheter arterial chemoembolization (tace) has been contra-indicated for the treatment of patients with hepatocellular carcinoma (hcc) and main portal vein (mpv) obstruction because of the potential risk of hepatic insufficiency resulting from ischemia after tace. the current co

AOSOP3 Combination of bevacizumab and er

AOSOP3 Combination of bevacizumab and erlotinib in the treatment of patients with advanced hepatocellular carcinoma with sorafenib-refractory disease: Results of a pilot phase II study

✍ T. Yau; H. Wong; P. Chan; T.J. Yao; T.T. Cheung; S.T. Fan; R.T. Poon 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 151 KB

370 INTERNAL RADIOTHERAPY WITH 90YTTRIUM

370 INTERNAL RADIOTHERAPY WITH 90YTTRIUM GLASS MICROSPHERES (THERASPHERE) FOR LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA: PROSPECTIVE VALIDATION OF SAFETY AND EFFICACY IN A EUROPEAN PILOT STUDY

✍ J.M. Ertle; G. Antoch; M. Hamami; A. Bockisch; G. Gerken; P. Hilgard 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Abstract No. 196: Worldwide trends in lo

Abstract No. 196: Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): 2nd interim analysis (IA; 1500 patients [pts]) of the GIDEON (global investigation of therapeutic decisions in HCC and of its treatment with sorafenib) study

✍ Geschwind, J.F.; Lencioni, R.; Marrero, J.; Venook, A.; Ye, S.; Nakajima, K.; Ku 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB